Literature DB >> 8600686

Histopathology of cholestasis.

V J Desmet1.   

Abstract

Cholestasis may be extrahepatic or intrahepatic in origin. The block in bile secretion may be complete or incomplete to variable extent. Complete cholestasis occurs in case of primary parenchymal disease (intrahepatic cholestasis) or total obstruction of extrahepatic bile ducts (extrahepatic cholestasis). Incomplete block in bile secretion is due to incomplete obstruction of intra- or extrahepatic bile ducts (intra- or extrahepatic cholestasis or both). Histologically, it is useful to distinguish between bilirubionstasis and cholate-stasis. Complete secretory block causes as early changers: bilirubinostasis (in hepatocytes, canaliculi and Kupffer cells) in acinar zone 3, and "ductular reaction" in acinar zone 1. The latter refers to an increase in periportal ductular profiles, associated with neutrophil infiltration. With longer duration of cholestasis, further lesions ensue: feathery degeneration of hepatocytes due to retention of detergent bile acids, cholestatic liver cell rosettes representing a shift from hepatocellular to biliary differentiation, xanthomatous cells reflecting hyperlipidemia, cholate stasis in acinar zone 1 due to overload of membrane-damaging bile acids, eventually paraportal bile infarcts, and progressive ductular reaction. The latter may be due to multiplication of pre-existing ductules, to metaplasia of periportal hepatocytes, or to activation of progenitor cells. It is invariably associated with periductular fibrosis: the pacemaker for increasing matrix deposition, resulting in biliary fibrosis and eventually in true biliary cirrhosis. Incomplete cholestasis (e.g. PBC, PSC) is characterized by absence of bilirubinostasis during long periods of time, whereas the afore mentioned features of chronic cholestasis do appear. Hence follows that the most reliable markers of chronic incomplete cholestasis are cholate stasis, cholestatic rosettes and ductular reaction. Bilirubinostasis is only a late and often ominous sign.

Entities:  

Mesh:

Year:  1995        PMID: 8600686

Source DB:  PubMed          Journal:  Verh Dtsch Ges Pathol        ISSN: 0070-4113


  9 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Characterization of animal models for primary sclerosing cholangitis (PSC).

Authors:  Peter Fickert; Marion J Pollheimer; Ulrich Beuers; Carolin Lackner; Gideon Hirschfield; Chantal Housset; Verena Keitel; Christoph Schramm; Hanns-Ulrich Marschall; Tom H Karlsen; Espen Melum; Arthur Kaser; Bertus Eksteen; Mario Strazzabosco; Michael Manns; Michael Trauner
Journal:  J Hepatol       Date:  2014-02-19       Impact factor: 25.083

3.  A histologic scoring system for prognosis of patients with alcoholic hepatitis.

Authors:  José Altamirano; Rosa Miquel; Aezam Katoonizadeh; Juan G Abraldes; Andrés Duarte-Rojo; Alexandre Louvet; Salvador Augustin; Rajeshwar P Mookerjee; Javier Michelena; Thomas C Smyrk; David Buob; Emmanuelle Leteurtre; Diego Rincón; Pablo Ruiz; Juan Carlos García-Pagán; Carmen Guerrero-Marquez; Patricia D Jones; A Sidney Barritt; Vicente Arroyo; Miquel Bruguera; Rafael Bañares; Pere Ginès; Juan Caballería; Tania Roskams; Frederik Nevens; Rajiv Jalan; Philippe Mathurin; Vijay H Shah; Ramón Bataller
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

4.  Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes.

Authors:  Tracy L Marion; Cassandra H Perry; Robert L St Claire; Kim L R Brouwer
Journal:  Toxicol Appl Pharmacol       Date:  2012-02-11       Impact factor: 4.219

5.  A novel method for establishment and characterization of extrahepatic bile duct epithelial cells from mice.

Authors:  Chengwei Chai; Shuaiyu Zheng; Jiexiong Feng; Xiaojuan Wu; Jixin Yang; Mingfa Wei
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-09-11       Impact factor: 2.416

6.  Study protocol of Phase 2 open-label multicenter randomized controlled trial for granulocyte-colony stimulating factor (GCSF) in post-Kasai Type 3 biliary atresia.

Authors:  Hoa Pham Anh Nguyen; Jinma Ren; Marilyn Butler; Henri Li; Saqib Qazi; Kamran Sadiq; Hieu Trung Dao; AiXuan Holterman
Journal:  Pediatr Surg Int       Date:  2022-04-07       Impact factor: 1.827

7.  Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice.

Authors:  Lindsey L Kennedy; Fanyin Meng; Julie K Venter; Tianhao Zhou; Walker A Karstens; Laura A Hargrove; Nan Wu; Konstantina Kyritsi; John Greene; Pietro Invernizzi; Francesca Bernuzzi; Shannon S Glaser; Heather L Francis; Gianfranco Alpini
Journal:  Lab Invest       Date:  2016-10-24       Impact factor: 5.662

8.  Cholestasis Differentially Affects Liver Connexins.

Authors:  Axelle Cooreman; Raf Van Campenhout; Sara Crespo Yanguas; Eva Gijbels; Kaat Leroy; Alanah Pieters; Andrés Tabernilla; Pieter Van Brantegem; Pieter Annaert; Bruno Cogliati; Mathieu Vinken
Journal:  Int J Mol Sci       Date:  2020-09-07       Impact factor: 5.923

9.  Long-term culture of cholangiocytes from liver fibro-granulomatous lesions.

Authors:  Luciana B Chiarini; Christina M Takiya; Radovan Borojevic; Alvaro N A Monteiro
Journal:  BMC Gastroenterol       Date:  2006-04-03       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.